Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Garenoxacin - FUJIFILM Toyama Chemical

Drug Profile

Garenoxacin - FUJIFILM Toyama Chemical

Alternative Names: BMS-284756; Des-F(6)-quinolone; Desquinolone; Garenoxacin mesilate hydrate; Garenoxacin mesylate; Geninax; Inforce; T-3811; T-3811-ME

Latest Information Update: 29 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taisho Pharmaceutical; Toyama Chemical
  • Developer FUJIFILM Toyama Chemical; Merck & Co; Taisho Pharmaceutical; Toyama Chemical
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gram-negative infections; Gram-positive infections; Otorhinolaryngological infections; Respiratory tract infections
  • No development reported Bacterial infections
  • Discontinued Acute exacerbations of chronic bronchitis; Acute sinusitis; Community-acquired pneumonia; Intra-abdominal infections; Skin and soft tissue infections

Most Recent Events

  • 25 Jul 2019 Registered for Respiratory tract infections in China (PO)
  • 25 Jul 2019 Fujifilm Toyama Chemical and Shenzhen Main Luck Pharmaceuticals plans to launch for Respiratory tract infections in China by March 2021
  • 25 Jul 2019 The National Medical Products Administration (NMPA) issues an imported drug license for garenoxacin for the treatment of Respiratory tract infections in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top